Straits Times Index
3,110.73 +36.47 (+1.19%) Nikkei
32,307.86 -550.45 (-1.68%) Hang Seng
16,334.37 -11.52 (-0.07%) FTSE 100
7,554.47 +40.75 (+0.54%) Bitcoin USD
43,931.98 -331.99 (-0.75%) CMC Crypto 200
914.81 +18.10 (+2.02%)
Vertex Pharmaceuticals Incorporated (VRTX)
After hours:
| Previous close | 353.95 |
| Open | 354.00 |
| Bid | 349.41 x 900 |
| Ask | 350.80 x 800 |
| Day's range | 348.46 - 354.35 |
| 52-week range | 282.21 - 387.42 |
| Volume | |
| Avg. volume | 1,210,545 |
| Market cap | 90.228B |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | 26.31 |
| EPS (TTM) | 13.31 |
| Earnings date | 05 Feb 2024 - 09 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 400.00 |
Motley FoolForget the "Magnificent Seven": Buy This Stock Instead
With the Nasdaq Composite up by 36% this year, those equities known as the "Magnificent Seven" have done quite a bit of the work. The company in question is biotech giant Vertex Pharmaceuticals (NASDAQ: VRTX).
Motley Fool2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
These businesses are on different growth trajectories, but both are leaders in their respective industries with untold potential ahead.
- Yahoo Finance Video
FDA approves gene-editing therapy for sickle cell disease
The FDA approved gene-editing therapy Casgevy to treat sickle cell disease. Developed by Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP), the one-time treatment harnesses gene editing advancements. Vertex CEO Dr. Reshma Kewalramani says the approach involves extracting a patient's stem cells, correcting the defect in those cells using CRISPR gene editing tools, then re-infusing the edited cells into the patient - relieving painful symptoms. Patients who undergo this $2.2 million procedure may eliminate painful sickle cell crises called VOC's. Kewalramani contrasts the cost against the $4-6 million lifetime price tag for conventional sickle cell management. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
